SPRAVATO® (esketamine)
What is SPRAVATO®?
Spravato is a groundbreaking treatment designed to bring new hope to those battling treatment-resistant depression. This innovative nasal spray works in a unique way, offering fast-acting relief by targeting areas of the brain linked to mood and emotional well-being.
For individuals who haven’t found success with traditional antidepressants, Spravato opens the door to brighter days and renewed possibilities.
Exceptional outcomes
Prescribed by experienced providers
Medically supervised
& FDA-approved
How does SPRAVATO® work?
SPRAVATO® works differently from traditional antidepressants. It targets the N-methyl-D-aspartate (NMDA) receptor, increasing glutamate activity in the brain. This process is believed to promote neuroplasticity—the formation of new neural connections that support positive thought patterns and behavioral changes, offering relief for those struggling with depression.
What conditions can be treated?
SPRAVATO® has been approved for the treatment of:
- Adults with treatment-resistant depression (those who have not had an adequate response to two or more antidepressants)
- Adults with Major Depressive Disorder experiencing suicidal thoughts or actions.
What to expect with SPRAVATO®
At every step, you’ll be guided by our experienced team.
Comprehensive evaluation
Comprehensive evaluation
Complete series
Complete series
Ongoing monitoring & support
Ongoing monitoring & support
SPRAVATO® vs. IM Ketamine
Not sure which one is a better fit for you? Click below to see the similarities and differences.
Why SPRAVATO®?
- Insurance-Covered: The only ketamine treatment covered by insurance for treatment-resistant depression (TRD).
- Proven Results: In clinical trials, patients taking SPRAVATO® along with oral antidepressants were less likely to experience a relapse compared to those taking a placebo with oral antidepressants
- Rapid Relief: Most patients experienced a significant reduction in depressive symptoms within just 24 hours.
Frequently asked questions
SPRAVATO® is a self-administered via nasal spray under medical supervision at our facility. Patients must remain in the clinic for at least two hours after treatment for monitoring.
Treatment begins with twice-weekly sessions for four weeks, then decreases to once weekly for four weeks. Ongoing maintenance varies based on individual response and provider recommendations.
Each session lasts about two hours to allow for administration, monitoring, and recovery before leaving the clinic.
Common side effects include dizziness, nausea, increased blood pressure, sedation, and dissociation. These effects typically subside within a few hours.
Some patients experience symptom relief within hours, while others may take several treatments to notice improvement.
Most insurance plans cover SPRAVATO® for treatment-resistant depression but a prior-authorization is required. If after your evaluation we think you would be a good fit for Spravato, we will submit and manage that prior authorization process on your behalf. Coverage varies, so check with your insurance carrier for details.
